Surmodics Stock Price, News & Analysis (NASDAQ:SRDX)

$29.00 -0.80 (-2.68 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$29.80
Today's Range$28.90 - $30.40
52-Week Range$21.90 - $34.15
Volume27,514 shs
Average Volume39,413 shs
Market Capitalization$398.86 million
P/E Ratio59.71
Dividend YieldN/A
Beta0.83

About Surmodics (NASDAQ:SRDX)

Surmodics logoSurmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio6.21%
Quick Ratio5.85%

Price-To-Earnings

Trailing P/E Ratio59.71
Forward P/E Ratio-65.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$73.11 million
Price / Sales5.20
Cash Flow$0.91 per share
Price / Cash31.70
Book Value$8.41 per share
Price / Book3.45

Profitability

Trailing EPS$0.29
Net Income$3.92 million
Net Margins5.37%
Return on Equity6.18%
Return on Assets5.11%

Miscellaneous

Employees257
Outstanding Shares13,100,000

Surmodics (NASDAQ:SRDX) Frequently Asked Questions

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) posted its quarterly earnings data on Wednesday, November, 8th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.19. The business earned $20.06 million during the quarter, compared to analyst estimates of $16.98 million. Surmodics had a return on equity of 6.18% and a net margin of 5.37%. View Surmodics' Earnings History.

Where is Surmodics' stock going? Where will Surmodics' stock price be in 2017?

2 Wall Street analysts have issued 1 year price targets for Surmodics' shares. Their forecasts range from $40.00 to $40.00. On average, they expect Surmodics' stock price to reach $40.00 in the next twelve months. View Analyst Ratings for Surmodics.

Who are some of Surmodics' key competitors?

Who are Surmodics' key executives?

Surmodics' management team includes the folowing people:

  • Susan E. Knight, Independent Chairman of the Board (Age 62)
  • Gary R. Maharaj, President, Chief Executive Officer, Director (Age 53)
  • Andrew D. C. LaFrence, Vice President of Finance and Information Systems and Chief Financial Officer (Age 53)
  • Thomas A. Greaney, Executive Vice President of Medical Devices (Age 50)
  • Bryan K. Phillips, Senior Vice President - Legal and Human Resources, General Counsel & Secretary (Age 45)
  • Charles W. Olson, Senior Vice President of Commercial and Business Development, Medical Devices (Age 52)
  • Joseph J. Stich, Vice President, General Manager - In Vitro Diagnostics (Age 51)
  • Timothy J. Arens, Vice President - Corporate Development and Strategy (Age 49)
  • Gregg S. Sutton, Vice President - Research & Development (Age 57)
  • Lisa Wipperman Heine, Director (Age 53)

Who owns Surmodics stock?

Surmodics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Trigran Investments Inc. (9.67%), Dimensional Fund Advisors LP (4.78%), Royce & Associates LP (2.60%), Disciplined Growth Investors Inc. MN (1.36%), Bank of New York Mellon Corp (1.30%) and Segall Bryant & Hamill LLC (0.96%). Company insiders that own Surmodics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Joseph J Stich, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for Surmodics.

Who sold Surmodics stock? Who is selling Surmodics stock?

Surmodics' stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Citadel Advisors LLC, Bank of New York Mellon Corp, Cornerstone Capital Management Holdings LLC., Prudential Financial Inc., Disciplined Growth Investors Inc. MN, OxFORD Asset Management LLP and Gabelli Funds LLC. Company insiders that have sold Surmodics company stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj and Joseph J Stich. View Insider Buying and Selling for Surmodics.

Who bought Surmodics stock? Who is buying Surmodics stock?

Surmodics' stock was bought by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Trigran Investments Inc., Schwab Charles Investment Management Inc., Condor Capital Management, Wells Fargo & Company MN, Macquarie Group Ltd., Dimensional Fund Advisors LP and SG Americas Securities LLC. View Insider Buying and Selling for Surmodics.

How do I buy Surmodics stock?

Shares of Surmodics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Surmodics' stock price today?

One share of Surmodics stock can currently be purchased for approximately $29.00.

How big of a company is Surmodics?

Surmodics has a market capitalization of $398.86 million and generates $73.11 million in revenue each year. The company earns $3.92 million in net income (profit) each year or $0.29 on an earnings per share basis. Surmodics employs 257 workers across the globe.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]


MarketBeat Community Rating for Surmodics (SRDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Surmodics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Surmodics (NASDAQ:SRDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.502.502.502.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $36.50$36.50$34.33$31.50
Price Target Upside: 32.49% upside32.49% upside24.62% upside20.46% upside

Surmodics (NASDAQ:SRDX) Consensus Price Target History

Price Target History for Surmodics (NASDAQ:SRDX)

Surmodics (NASDAQ:SRDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Lake Street CapitalInitiated CoverageBuy -> Buy$40.00MediumView Rating Details
6/27/2017AegisInitiated CoverageBuyHighView Rating Details
11/21/2016Barrington ResearchDowngradeOutperform -> Market PerformN/AView Rating Details
10/6/2016SidotiDowngradeBuy -> Neutral$33.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Surmodics (NASDAQ:SRDX) Earnings History and Estimates Chart

Earnings by Quarter for Surmodics (NASDAQ:SRDX)

Surmodics (NASDAQ SRDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q4 2017($0.01)$0.18$16.98 million$20.06 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.01)$0.09$15.98 million$17.80 millionViewListenView Earnings Details
4/27/2017Q2 2017$0.07$0.05$16.21 million$17.50 millionViewN/AView Earnings Details
2/2/2017Q117$0.09$0.19$15.81 million$17.80 millionViewListenView Earnings Details
11/16/2016Q4 2016$0.09$0.26$16.09 million$18.20 millionViewListenView Earnings Details
7/28/2016Q316$0.12$0.37$16.31 million$19.97 millionViewListenView Earnings Details
5/2/2016Q2$0.09$0.20$14.71 million$16.70 millionViewListenView Earnings Details
1/28/2016Q116$0.17$0.38$14.58 million$16.50 millionViewListenView Earnings Details
11/10/2015Q415$0.19$0.30$15.30 million$17.40 millionViewListenView Earnings Details
8/5/2015Q315$0.21$0.26$14.86 million$15.90 millionViewListenView Earnings Details
4/30/2015Q2$0.20$0.19$14.09 million$14.40 millionViewListenView Earnings Details
1/29/2015Q414$0.21$0.25$14.30 million$14.20 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.26$14.90 million$15.30 millionViewN/AView Earnings Details
7/31/2014Q214$0.23$0.27$14.84 million$14.62 millionViewListenView Earnings Details
5/1/2014Q114$0.20$0.22$14.40 million$13.60 millionViewListenView Earnings Details
1/30/2014Q413$0.21$0.21$14.15 million$13.90 millionViewListenView Earnings Details
11/5/2013Q313$0.22$0.26$14.32 million$14.30 millionViewListenView Earnings Details
7/31/2013Q3 2013$0.21$0.22$15.03 million$14.29 millionViewListenView Earnings Details
5/7/2013Q2 2013$0.21$0.20$13.92 million$13.70 millionViewListenView Earnings Details
1/30/2013Q1 2013$0.18$0.29$13.63 million$13.85 millionViewListenView Earnings Details
11/6/2012Q412$0.17$0.17$13.83 million$13.80 millionViewN/AView Earnings Details
8/1/2012$0.14$0.17ViewN/AView Earnings Details
5/8/2012$0.15$0.14ViewN/AView Earnings Details
11/3/2011$0.05$0.06ViewN/AView Earnings Details
8/3/2011$0.04$0.13ViewN/AView Earnings Details
4/27/2011$0.08ViewN/AView Earnings Details
1/26/2011$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Surmodics (NASDAQ:SRDX) Earnings Estimates

2017 EPS Consensus Estimate: $0.18
2018 EPS Consensus Estimate: $0.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.05$0.12$0.09
Q2 20172$0.05$0.08$0.07
Q3 20172$0.00$0.03$0.02
Q4 20172($0.01)$0.04$0.02
Q1 20181$0.01$0.01$0.01
Q2 20181$0.06$0.06$0.06
Q3 20181$0.06$0.06$0.06
Q4 20181$0.07$0.07$0.07
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Surmodics (NASDAQ:SRDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Surmodics (NASDAQ SRDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 85.64%
Insider Trades by Quarter for Surmodics (NASDAQ:SRDX)
Insider Trades by Quarter for Surmodics (NASDAQ:SRDX)

Surmodics (NASDAQ SRDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Charles W OlsonVPSell801$27.85$22,307.85View SEC Filing  
9/11/2017Joseph J. StichVPSell1,000$27.28$27,280.00View SEC Filing  
8/7/2017Gary R MaharajCEOSell5,000$25.75$128,750.00View SEC Filing  
7/3/2017Gary R MaharajCEOSell5,000$28.03$140,150.00View SEC Filing  
6/16/2017Bryan K PhillipsSVPSell1,226$24.85$30,466.10View SEC Filing  
6/9/2017Joseph J StichVPSell1,000$25.31$25,310.00View SEC Filing  
6/5/2017Gary R MaharajCEOSell2,702$25.09$67,793.18View SEC Filing  
4/3/2017Gary R. MaharajCEOSell584$25.00$14,600.00View SEC Filing  
3/6/2017Joseph J. StichVPSell1,000$24.73$24,730.00View SEC Filing  
12/22/2016Charles W OlsonVPSell1,201$26.00$31,226.00View SEC Filing  
12/8/2016Charles W OlsonVPSell3,699$26.02$96,247.98View SEC Filing  
12/5/2016Joseph J StichVPSell1,000$23.97$23,970.00View SEC Filing  
12/2/2016Bryan K PhillipsSVPSell1,264$23.90$30,209.60View SEC Filing  
11/25/2016Charles W OlsonVPSell500$26.02$13,010.00View SEC Filing  
11/7/2016Gary R MaharajCEOSell5,000$25.22$126,100.00View SEC Filing  
10/3/2016Gary R. MaharajCEOSell5,000$29.55$147,750.00View SEC Filing  
8/17/2016Charles W OlsonVPSell9,936$28.98$287,945.28View SEC Filing  
8/15/2016Susan E. KnightDirectorSell1,548$28.64$44,334.72View SEC Filing  
8/1/2016Charles W OlsonVPSell12,500$27.08$338,500.00View SEC Filing  
6/14/2016Bryan K PhillipsSVPSell1,816$23.44$42,567.04View SEC Filing  
6/10/2016Joseph J StichVPSell1,000$23.33$23,330.00View SEC Filing  
5/27/2016Susan E KnightDirectorSell1,001$22.71$22,732.71View SEC Filing  
3/4/2016Timothy J ArensVPSell10,291$18.43$189,663.13View SEC Filing  
12/4/2015Joseph J StichVPSell1,000$21.18$21,180.00View SEC Filing  
9/4/2015Joseph J StichVPSell1,000$23.57$23,570.00View SEC Filing  
6/5/2015Joseph J StichVPSell1,000$23.84$23,840.00View SEC Filing  
5/22/2015Bryan K PhillipsSVPSell7,293$25.25$184,148.25View SEC Filing  
12/29/2014Charles W OlsonVPSell5,083$21.98$111,724.34View SEC Filing  
12/8/2014Charles W OlsonVPSell3,365$21.66$72,885.90View SEC Filing  
11/19/2014Timothy J ArensVPSell10,330$21.02$217,136.60View SEC Filing  
5/8/2014Susan KnightDirectorBuy1,500$20.36$30,540.00View SEC Filing  
12/4/2013Bryan PhillipsSVPSell16,236$22.95$372,616.20View SEC Filing  
5/15/2013Mark A LehmanInsiderSell1,693$26.55$44,949.15View SEC Filing  
8/10/2012Value Lp StarboardMajor ShareholderSell257,560$17.74$4,569,114.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Surmodics (NASDAQ SRDX) News Headlines

Source:
DateHeadline
Reviewing Surmodics (SRDX) and Its RivalsReviewing Surmodics (SRDX) and Its Rivals
www.americanbankingnews.com - December 12 at 7:34 PM
Surmodics (SRDX) Rating Lowered to Sell at BidaskClubSurmodics (SRDX) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - December 12 at 5:58 PM
Head to Head Survey: Surmodics (SRDX) & Its CompetitorsHead to Head Survey: Surmodics (SRDX) & Its Competitors
www.americanbankingnews.com - December 10 at 9:30 AM
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : December 8, 2017SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : December 8, 2017
finance.yahoo.com - December 8 at 11:17 AM
Contrasting Surmodics (SRDX) and Its PeersContrasting Surmodics (SRDX) and Its Peers
www.americanbankingnews.com - December 7 at 7:24 AM
SurModics, Inc. :SRDX-US: Earnings Analysis: 2017 By the Numbers : December 5, 2017SurModics, Inc. :SRDX-US: Earnings Analysis: 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 12:48 PM
Surmodics Inc (SRDX) Files 10-K for the Fiscal Year Ended on September 30, 2017Surmodics Inc (SRDX) Files 10-K for the Fiscal Year Ended on September 30, 2017
finance.yahoo.com - December 2 at 8:17 AM
Contrasting Surmodics (SRDX) & The CompetitionContrasting Surmodics (SRDX) & The Competition
www.americanbankingnews.com - November 20 at 1:40 PM
SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : November 14, 2017SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : November 14, 2017
finance.yahoo.com - November 15 at 10:56 AM
Surmodics, Inc. (SRDX) Stock Rating Lowered by Zacks Investment ResearchSurmodics, Inc. (SRDX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:50 AM
Surmodics Inc (SRDX): What Can We Expect In The Future?Surmodics Inc (SRDX): What Can We Expect In The Future?
finance.yahoo.com - November 14 at 8:13 AM
Surmodics, Inc. (SRDX) Receives Consensus Rating of "Hold" from BrokeragesSurmodics, Inc. (SRDX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 14 at 1:50 AM
Head-To-Head Analysis: Antares Pharma (ATRS) and Surmodics (SRDX)Head-To-Head Analysis: Antares Pharma (ATRS) and Surmodics (SRDX)
www.americanbankingnews.com - November 13 at 1:48 AM
Surmodics, Inc. (SRDX) Releases  Earnings Results, Beats Estimates By $0.19 EPSSurmodics, Inc. (SRDX) Releases Earnings Results, Beats Estimates By $0.19 EPS
www.americanbankingnews.com - November 10 at 4:39 PM
Edited Transcript of SRDX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of SRDX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 7:02 PM
Surmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 GuidanceSurmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance
www.businesswire.com - November 9 at 1:56 PM
Surmodics, Inc. (SRDX) to Release Earnings on TuesdaySurmodics, Inc. (SRDX) to Release Earnings on Tuesday
www.americanbankingnews.com - November 7 at 3:04 AM
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : November 2, 2017SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : November 2, 2017
finance.yahoo.com - November 2 at 9:11 AM
Surmodics to Webcast Fourth Quarter 2017 Earnings Conference Call on November 8Surmodics to Webcast Fourth Quarter 2017 Earnings Conference Call on November 8
finance.yahoo.com - October 28 at 7:08 AM
Surmodics to Present at Canaccord Genuity Medical Technologies and Diagnostics ForumSurmodics to Present at Canaccord Genuity Medical Technologies and Diagnostics Forum
finance.yahoo.com - October 28 at 7:08 AM
Surmodics Announces First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil® Drug-Coated BalloonSurmodics Announces First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil® Drug-Coated Balloon
finance.yahoo.com - October 24 at 10:28 AM
ETFs with exposure to SurModics, Inc. : October 23, 2017ETFs with exposure to SurModics, Inc. : October 23, 2017
finance.yahoo.com - October 24 at 10:28 AM
Surmodics, Inc. (SRDX) Receives Average Rating of "Hold" from AnalystsSurmodics, Inc. (SRDX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 20 at 2:48 AM
SurModics, Inc. :SRDX-US: Earnings Analysis: Q3, 2017 By the Numbers : October 5, 2017SurModics, Inc. :SRDX-US: Earnings Analysis: Q3, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 6 at 12:24 PM
ETFs with exposure to SurModics, Inc. : October 6, 2017ETFs with exposure to SurModics, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 12:24 PM
Surmodics, Inc. (SRDX) Given Average Recommendation of "Hold" by BrokeragesSurmodics, Inc. (SRDX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 25 at 2:38 AM
Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation CatheterSurmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter
finance.yahoo.com - September 20 at 9:22 AM
Surmodics, Inc. (SRDX) VP Charles W. Olson Sells 801 SharesSurmodics, Inc. (SRDX) VP Charles W. Olson Sells 801 Shares
www.americanbankingnews.com - September 19 at 8:32 PM
Surmodics Announces Global Approvals Of .014" Low-Profile PTA Balloon Dilation CatheterSurmodics Announces Global Approvals Of .014" Low-Profile PTA Balloon Dilation Catheter
www.thestreet.com - September 19 at 8:01 AM
Surmodics Presents Encouraging SurVeil DCB Data at VIVA MeetSurmodics Presents Encouraging SurVeil DCB Data at VIVA Meet
www.zacks.com - September 15 at 9:16 AM
Six-Month Data from the Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2017Six-Month Data from the Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2017
finance.yahoo.com - September 14 at 10:40 AM
Insider Selling: Surmodics, Inc. (SRDX) VP Sells 1,000 Shares of StockInsider Selling: Surmodics, Inc. (SRDX) VP Sells 1,000 Shares of Stock
www.americanbankingnews.com - September 13 at 9:16 PM
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : September 5, 2017SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : September 5, 2017
finance.yahoo.com - September 6 at 8:36 AM
Surmodics, Inc. (SRDX) Given Average Recommendation of "Hold" by AnalystsSurmodics, Inc. (SRDX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 31 at 2:46 AM
SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : August 15, 2017SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : August 15, 2017
finance.yahoo.com - August 16 at 7:47 AM
Insider Selling: Surmodics, Inc. (SRDX) CEO Sells 5,000 Shares of StockInsider Selling: Surmodics, Inc. (SRDX) CEO Sells 5,000 Shares of Stock
www.americanbankingnews.com - August 9 at 9:06 PM
Q4 2017 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Lowered by Barrington ResearchQ4 2017 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Lowered by Barrington Research
www.americanbankingnews.com - August 7 at 8:02 AM
Surmodics, Inc. (NASDAQ:SRDX) Given Average Rating of "Hold" by AnalystsSurmodics, Inc. (NASDAQ:SRDX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - August 6 at 7:10 AM
Surmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 GuidanceSurmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 Guidance
finance.yahoo.com - August 4 at 8:30 AM
SurModics posts 3Q profitSurModics posts 3Q profit
finance.yahoo.com - August 4 at 8:30 AM
Edited Transcript of SRDX earnings conference call or presentation 3-Aug-17 12:30pm GMTEdited Transcript of SRDX earnings conference call or presentation 3-Aug-17 12:30pm GMT
finance.yahoo.com - August 4 at 8:30 AM
Surmodics, Inc. (NASDAQ:SRDX) Posts Quarterly  Earnings Results, Beats Expectations By $0.10 EPSSurmodics, Inc. (NASDAQ:SRDX) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - August 3 at 8:52 PM
Surmodics, Inc. (SRDX) Releases FY17 Earnings GuidanceSurmodics, Inc. (SRDX) Releases FY17 Earnings Guidance
www.americanbankingnews.com - August 3 at 9:26 AM
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : August 2, 2017SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : August 2, 2017
finance.yahoo.com - August 3 at 7:29 AM
SurModics (SRDX) Announces Approval to Initiate Pivotal Trial of the SurVeil Drug-Coated BalloonSurModics (SRDX) Announces Approval to Initiate Pivotal Trial of the SurVeil Drug-Coated Balloon
www.streetinsider.com - July 27 at 7:48 AM
Surmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3Surmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3
finance.yahoo.com - July 26 at 8:13 AM
Surmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil™ Drug-Coated BalloonSurmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil™ Drug-Coated Balloon
finance.yahoo.com - July 26 at 8:13 AM
Surmodics, Inc. (NASDAQ:SRDX) Set to Announce Earnings on WednesdaySurmodics, Inc. (NASDAQ:SRDX) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - July 19 at 9:14 AM
Financial Survey: Surmodics (SRDX) and H. B. Fuller Company (FUL)Financial Survey: Surmodics (SRDX) and H. B. Fuller Company (FUL)
www.americanbankingnews.com - July 15 at 10:08 AM
Surmodics, Inc. (NASDAQ:SRDX) Coverage Initiated by Analysts at Lake Street CapitalSurmodics, Inc. (NASDAQ:SRDX) Coverage Initiated by Analysts at Lake Street Capital
www.americanbankingnews.com - July 14 at 9:48 AM

SEC Filings

Surmodics (NASDAQ:SRDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Surmodics (NASDAQ:SRDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Surmodics (NASDAQ SRDX) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.